Enliven Therapeutics (ELVN) News
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
46.53+0.12 (+0.26%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ELVN news summary
We found 4 recent headlines mentioning Enliven Therapeutics (ELVN): 0 in the past week and 2 in the past 30 days, most often from PR Newswire, Seeking Alpha, Nasdaq. For price context, ELVN is up 0.26% at $46.53. The most recent story, "Enliven Therapeutics GAAP EPS of -$0.36", was published by Seeking Alpha on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Enliven Therapeutics headlines
- Enliven Therapeutics GAAP EPS of -$0.36Seeking Alpha
- Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business UpdateReached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash…PR Newswire
- Enliven Appoints Former Antiva CEO Kristine Ball To Board As Relcobatinib Nears Phase 3 Launch(RTTNews) - Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company focused on small molecule therapeutics, announced the appointment of Kristine Ball to its Board of Directors,…NasdaqELVN, ET
- Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearAccomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage development and…PR Newswire